Wednesday, October 22, 2014

Clinical Lipidology Congress Vienna, Austria

The 2nd World Congress on Clinical Lipidology will be held on 5-7 December 2014 in Vienna, Austria.

This extraordinary event will provide state of the art educational lectures in the field of clinical lipidology, focusing on practical lipid management including difficult to treat hyperlipidemias, genetic dyslipidemias, screening, dietary and nutraceutical approaches and case studies. Major emphasis will be given to new therapeutics, diagnosis and management of high risk patients.

The speakers are internationally recognized experts in the field of Dyslipidemias and will be available for small group discussions and workshops. In addition debate sessions will highlight topics that are currently controversial.

Don’t miss this unique opportunity.

Further details are found at: www.clinical-lipidology.com

Key Note Speakers

Professor Philip Barter is President of the International Atherosclerosis Society.
He is also a Conjoint Professor of Medicine at the University of New South Wales in Sydney Australia. His basic research interests are plasma lipids and lipoproteins, specifically high density lipoproteins, the factors that regulate them and the mechanism by which they protect against cardiovascular disease.
    
Professor Klaus G Parhofer, MD is a Professor of Endocrinology and Metabolism at the Ludwig Maximilians University of Munich in Germany. He is the head of the Division of Metabolism and Endocrinology at the Medical Department 2 of the university. His research focuses on lipoprotein metabolism, particularly diabetic dyslipoproteinemia, postprandial lipoprotein metabolism and LDL apheresis.

Workshops

Don’t miss these workshops to be held at LIPIDS 2014 Congress.

1.    Lipid Management For Primary Care
2.    Management Of Paediatric Dyslipidemia                                           
3.    Statin Resistance/Intolerance
4.    Lipid Management In Diabetes And Chronic Kidney Disease
5.    Difficult To Treat Hyperlipidemia
6.    Novel lipid lowering therapies, Focus on PCSK9


No comments:

Post a Comment